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AbstrAct
Breathlessness is among the most common and 
deteriorating symptoms in patients with advanced cancer, 
which may worsen towards the end of life. Breathlessness in 
patients with estimated life expectancy of weeks to days has 
unique clinical features: it tends to worsen rapidly over days 
to hours as death approaches often despite current symptom 
control measures. Breathlessness in patients during the last 
weeks to days of life can be called ‘terminal breathlessness’. 
While evidence has accumulated for the management 
of breathlessness in patients with cancer who are not 
dying, such evidence may not be fully applied to terminal 
breathlessness. Only a few studies have investigated the best 
practice of terminal breathlessness in patients with cancer. 
In this paper, we summarise the current evidence for the 
management of terminal breathlessness, and propose future 
directions of clinical research.
IntroduCtIon
Breathlessness, or dyspnoea, is among the 
most common and deteriorating symptoms in 
patients with advanced cancer.1–5 Breathless-
ness tends to worsen towards the last weeks 
to days of life, even with specialist- level pallia-
tive care.3 6 7 Breathlessness in patients during 
the last weeks to days of life has unique clin-
ical features: it may worsen rapidly over days 
to hours as death approaches, and is often 
less responsive to current palliative symptom 
control measures, therefore at times requiring 
palliative sedation.3 6 8 Timely assessment and 
proactive management of dyspnoea in such 
patients are of paramount importance. In this 
paper, we propose the concept of ‘terminal 
breathlessness’ as compared with a well- defined 
syndrome of chronic breathlessness, summa-
rise current evidence of its management and 
discuss future directions of clinical research on 
terminal breathlessness in patients with cancer.
terminology of ‘chronic breathlessness 
syndrome’ and ‘terminal breathlessness’
Chronic breathlessness syndrome
‘Chronic breathlessness syndrome’ has 
recently been defined by international experts 
as ‘breathlessness that persists despite optimal 
treatment of the underlying pathophysiology 
and that results in disability’.9 The severity 
of chronic breathlessness can fluctuate over 
years, and markedly impact on the quality of 
life.10 11 Likewise, ‘episodic breathlessness’ has 
been defined as ‘one form of breathlessness 
characterized by a severe worsening of breath-
lessness intensity or unpleasantness beyond 
usual fluctuations in the patient’s perception’, 
which can lead to high levels of anxiety.12 
Chronic breathlessness and episodic breath-
lessness are sometimes discussed as entities 
equivalent to chronic pain and breakthrough 
pain, respectively.12 13 Several randomised 
controlled trials (RCT) and systematic reviews 
have been conducted in the management of 
chronic breathlessness of patients with various 
diseases.14–18 A low- dose sustained- release 
morphine has now been approved for use in 
the symptomatic reduction of chronic breath-
lessness in Australia.19
Terminal breathlessness
Prior literature has largely focused on breath-
lessness specifically in patients who are not 
dying, and thus, such evidence may not be 
fully applied to breathlessness in patients 
with an estimated life expectancy of weeks to 
days. In the USA, the Medicare criteria for 
hospice eligibility of patients with advanced 
lung disease, the ‘terminal stage’ was defined 
as life expectancy of 6 months or less.20 In this 
paper, we tentatively define ‘terminal breath-
lessness’ (or ‘terminal dyspnea’) as breath-
lessness in patients with an estimated life 
expectancy of weeks to days. Similar termi-
nology is also proposed in ‘terminal agitation’ 
in dying patients, in whom the treatment goal 
is to relieve agitation rather than to reverse 
delirium.21 22
International guidelines recently 
recognised breathlessness as a frequent and 
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last phase of life.23 24 They indicate that the focus of treat-
ment in this phase shifts to pharmacological if existing 
treatment is insufficient, aggressive symptom relief may 
be required and human attendance and empathy are 
paramount.23 24
Measurements of terminal breathlessness
Breathlessness is a subjective sensation by definition, and 
should ideally be evaluated by patient- reported outcomes. 
As death approaches, however, subjective assessment 
can become increasingly challenging, as the level of 
consciousness tends to inevitably worsen.6 8 At present, 
there is no international consensus on how to measure 
breathlessness subjectively in patients with an impaired 
communication capacity.
Proxy rating of breathlessness has been used with or 
without reference to valid and reliable scales (eg, Inte-
grated Palliative care Outcome Scale (IPOS), Support 
Team Assessment Schedule (STAS))25 26 as well as objec-
tive signs potentially indicating the presence of breath-
lessness (eg, Respiratory Distress Observation Scale 
(RDOS)).27 However, proxy rating may not fully reflect 
subjective perception. A cross- sectional survey among 
patients with advanced cancer with breathlessness 
showed that physiological measures could not reliably 
inform about patients’ expression of breathlessness.28 
For example, the RDOS only had a weak correlation with 
patients’ expression of breathlessness (r=0.35).28 While 
patients’ expression of breathlessness was correlated 
moderately with family caregivers’ (r=0.68) and nurses’ 
(r=0.50) assessment, families overestimated while nurses 
underestimated breathlessness compared with patients. 
Moreover, a proxy rating could be affected by altered end- 
of- life respiratory patterns, and complicated by coexisting 
symptoms (eg, pain and anxiety), which could be influ-
enced by treatment such as opioids and sedatives. The 
identification of biological signs of a perceived sensation 
of breathlessness at the cerebral level would help eval-
uate the presence and intensity of breathlessness in non- 
communicative patients; however, such evaluation has yet 
to be investigated.
Current evIdenCe supportIng treatMent for terMInal 
breathlessness
Few studies have investigated the best practice for 
patients with cancer with terminal breathlessness, that is, 
breathlessness in patients with estimated life expectancy 
of weeks to days. A recent systematic review of literature 
published until 2016 identified only five studies (two RCTs 
and three prospective cohort studies) that investigated 
the effectiveness of drug therapy for breathlessness in 
the last days of life.29 Several new papers have since been 
published.23 30–32 Below is a summary of available evidence 
for the main treatment modalities for breathlessness and 
related conditions in patients with cancer with estimated 
life expectancy of weeks to days.
opioids
Morphine
Morphine has been used as the first- line pharmacolog-
ical therapy for alleviating breathlessness in patients with 
advanced cancer throughout the world. Multiple clinical 
guidelines recommend morphine for cancer breathless-
ness in general.23 24 31 33 In this situation, the recommen-
dations are based on studies of single- dose administra-
tion of morphine involving patients with relatively good 
condition.34 35 While these studies showed the efficacy 
of morphine for cancer breathlessness compared with a 
placebo, the efficacy of its regular or continuous adminis-
tration has not been confirmed. In addition, these studies 
included only cognitively competent patients with cancer 
with breathlessness. In clinical practice, morphine is 
widely used in various forms including continuous intra-
venous/subcutaneous infusion to ensure timely titration, 
rapid breathlessness relief and the avoidance of unneces-
sary adverse events in the setting of clinical deterioration 
and organ dysfunction during the last weeks to days of 
life.32 36 37 Thus, it is uncertain whether these results can 
be applied to patients with cancer who are very close to 
death.
One preliminary RCT explored the effects of morphine 
with or without midazolam on breathlessness in patients 
with cancer whose life expectancy was less than a week.38 
In this study, the investigators compared three treat-
ment regimens (around- the- clock (atc) morphine with 
midazolam as needed; atc midazolam with morphine as 
needed; or atc morphine plus midazolam with morphine 
as needed).38 Median breathlessness intensity within 
48 hours after starting the study medications in the 
regular morphine group was not significantly different 
from those in the regular midazolam group. A recent 
systematic review identified no major safety concerns 
regarding the use of morphine, other opioids, or midaz-
olam for breathlessness in the dying.29
Other opioids
No clinical trials have been conducted to confirm the 
effects of opioids other than morphine on breathless-
ness in patients with cancer with estimated life expec-
tancy of weeks to days. Clinical guidelines suggest that 
hydromorphone or oxycodone can be used for breath-
lessness in patients with advanced cancer as an alterna-
tive to morphine, or that opioid doses can be increased 
by 25% for non- opioid- naïve patients.23 24 31 However, 
robust evidence supporting the use of opioids other than 
morphine for cancer breathlessness in this situation has 
been lacking and there may not be a class effect.39 Only 
one study evaluated the effectiveness of hydromorphone 
for breathlessness in terminally ill patients with cancer who 
were admitted to a palliative care unit (mean survival, 22 
days).40 The patients experienced a significant decrease 
in breathlessness intensity over 2 hours without devel-
oping clinically significant respiratory depression. Two 
retrospective studies examined the effect of oxycodone 
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In one study, breathlessness improved in 39 of 44 patients 
(88.6%) after the administration of subcutaneous oxyco-
done infusion.41 In the other study involving 19 patients 
with cancer with breathlessness (median survival, 6 days), 
68.4% of them showed a response to intravenous oxyco-
done infusion within 3 days.30
Little is known about the effect of fentanyl on breathless-
ness in patients with cancer with estimated life expectancy 
of weeks to days. One exploratory observational study 
examined the effect of intravenous fentanyl on breath-
lessness in patients with cancer close to death.42 Although 
7 of 16 patients responded to intravenous fentanyl, the 
study design and high attrition rate precluded any conclu-
sions regarding its effect. Thus, the effects of fentanyl on 
terminal breathlessness remain unknown.
benzodiazepines
It is evident that breathlessness closely interacts with 
anxiety in patients with advanced cancer.43 44 Benzodi-
azepines are anxiolytics, and could thus relieve breath-
lessness. Like opioids, benzodiazepines have been widely 
used and recommended in palliating intense symptoms 
including breathlessness at the end of life.24 36 A meta- 
analysis of benzodiazepines for the treatment of patients 
with cancer breathlessness (not specific for terminal 
breathlessness) found no significant benefit of benzodi-
azepines over a placebo or morphine.45 However, only a 
few heterogeneous studies were included. Clinical guide-
lines and international experts suggested that benzodiaz-
epines have additional benefit in palliating breathlessness 
not responding to opioids in patients with cancer close to 
death.23 24 36 46 47 In patients with cancer with estimated life 
expectancy of weeks or longer, the use of benzodiazepine 
for breathlessness may need to be limited to those who 
have been treated with opioids or other interventions, 
as they could potentially worsen sedation and delirium. 
In contrast, in patients with cancer with estimated life 
expectancy of days who suffer from breathlessness not 
responding to symptomatic treatment, benzodiazepines 
are often used for palliative sedation.24 29 47
Strictly speaking, however, it remains unclear whether 
benzodiazepines alone are more effective for terminal 
breathlessness than opioids alone, whether the combi-
nation of benzodiazepine plus an opioid is more effec-
tive than each of them alone and what types of terminal 
breathlessness are the appropriate target of benzodi-
azepines (eg, terminal breathlessness with coexisting 
anxiety).
Corticosteroids
An elevated inflammatory response in patients with 
advanced cancer could contribute to breathlessness.48 
Corticosteroids could thus modulate the sensation 
of breathlessness with their potent anti- inflammatory 
activity. The effects of corticosteroids for breathless-
ness in patients with cancer have been suggested in 
a pilot RCT, several prospective observational studies 
and case reports.49–54 Yet, the indications and doses of 
corticosteroids for cancer breathlessness have not been 
established. Clinical guidelines recommend that corti-
costeroids be indicated for breathlessness due to specific 
conditions (eg, lymphangitis carcinomatosis, superior 
vena cava syndrome and airway obstruction), rather 
than for breathlessness of any aetiology, based on limited 
evidence.24 31
However, no study has confirmed the effects of corti-
costeroids on terminal breathlessness. Although cortico-
steroids are well tolerated by patients with cancer with 
dyspnoea in general,55 they may cause psychoactive side 
effects in patients with cancer during the last weeks to 
days of life. It remains uncertain whether the effective-
ness exceeds their risks in this phase.
supplemental oxygen
No evidence exists that supplemental oxygen relieves 
breathlessness, unless the patient suffers from 
hypoxia.56 57 Clinical guidelines essentially recommend 
oxygen therapy only for breathlessness in patients with 
hypoxia, although its use may be permissible if subjective 
relief is reported.23 24 31 In daily practice, however, oxygen 
therapy is widely used in the clinical setting of breathless-
ness in patients with terminal cancer irrespective of the 
presence of hypoxaemia.58 59 Balance should be aimed 
for between the benefit and potential disadvantages of 
oxygen therapy (eg, being a burdensome intervention 
requiring tubing and tanks, having to wear a mask when 
the person may still want to try to speak, the drying effects 
of oxygen on mucosa), especially in non- hypoxic patients 
with estimated life expectancy of weeks to days.
One small randomised trial examined the use of 
bilevel positive airway pressure (BiPAP) and high- flow 
oxygen therapy in hospitalised patients with advanced 
cancer. Both modalities were correlated with a signifi-
cant reduction in breathlessness scores, although there 
were no differences between the two groups.60 Another 
randomised trial compared BiPAP with the venturi mask, 
and confirmed the benefit for breathlessness, particularly 
in patients with hypoventilation.61 Although these modal-
ities may be useful for breathlessness relief if deemed clin-
ically appropriate, not all patients can tolerate them and 
further research is needed.
non-pharmacological treatment
Recent systematic reviews on non- pharmacological inter-
ventions for breathlessness relief in patients with advanced 
diseases showed the effectiveness of fan therapy, neuroe-
lectrical muscle stimulation, chest wall vibration, walking 
aids, breathing training and holistic services.62–65 Among 
these, fan therapy may be readily available for patients 
with cancer with terminal breathlessness. In a recent 
parallel- arm RCT that evaluated the effect of fan therapy 
on breathlessness in 40 terminally ill patients with cancer 
compared with a fan- to- legs group, the mean breathless-
ness scores decreased more significantly in the interven-
tion group.66 A recent meta- analysis also demonstrated the 
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compared with a control group.64 As evidence is limited, 
it is unclear whether non- pharmacological management 
other than fan therapy is effective for terminal breath-
lessness. However, patients with terminal breathlessness 
may benefit from holistic services (eg, breathing thera-
pists, person- centred dignified care) which have recently 
been shown to reduce distress and improve psychological 
outcomes in patients with advanced disease and chronic 
breathlessness.65
breathlessness not responding to symptomatic treatment
Breathlessness accounts for the majority of end- of- life 
suffering alongside delirium, for which palliative seda-
tion is one of the therapeutic options.47 67–70 A benzodiaz-
epine is the most common class of medication prescribed 
as a sedative in patients who have persistent intractable 
breathlessness despite the use of opioids.46 47 67–70
Guidelines and expert reviews recommend that seda-
tives should first be titrated to a minimal dose required 
to provide adequate palliation of suffering, rather than 
to continuously induce unconsciousness.71–74 As part 
of efforts to standardise end- of- life treatment, a repro-
ducible protocol of proportional midazolam use has 
recently been proposed that reflects the treatment inten-
tion and expected outcome.71 75 However, it remains 
unknown when breathlessness should be considered non- 
responding to symptomatic treatment, and how best seda-
tives should be titrated to relieve persistent intractable 
breathlessness in particular.
other issues in the last days of life
Respiratory secretion, especially death rattle, and changes 
in respiratory patterns (eg, Cheyne- Stokes breathing and 
respiration with mandibular movement) are often seen 
during the last days of life.8 23 24 These may lead to distress 
in families; while clinicians have traditionally believed 
there is no patient distress caused by death rattle and 
changes in respiratory patterns developed in the context 
of declining consciousness, whether the patient perceives 
distress remains controversial.76–78
Anticholinergics have been used to reduce respiratory 
secretion; however, systematic reviews revealed no addi-
tional benefit of medications or non- pharmacological 
treatments compared with a placebo.79 80 A prophylactic 
use of anticholinergics has recently been proposed to 
prevent death rattle but such a suggestion is without 
sufficient evidence of benefit.77 Therefore, the evidence 
for pharmacological management to reduce secretions 
is controversial at present. Repositioning of the patients 
and oropharyngeal suctioning can be effective if gently 
performed, but could cause discomfort in imminently 
dying patients.81 Educating family caregivers is of para-
mount importance.78
unanswered researCh questIons In terMInal 
breathlessness
As mentioned above, numerous clinical questions have yet 
to be answered regarding the assessment and treatment of 
patients with terminal breathlessness. This may be in part 
because terminal breathlessness has not necessarily been 
regarded as a symptom with unique features, and because 
conducting clinical trials involving patients with an esti-
mated life expectancy of weeks to days is challenging due 
to practical and ethical concerns.
However, recent international efforts have paved the 
way towards building high- quality evidence in the manage-
ment of previously ill- defined symptoms or discomfort in 
this population. For example, a consensus definition of 
chronic breathlessness syndrome has widely raised recog-
nition of this hidden discomfort, and led to a number 
of clinical trials with various treatment modalities.9 14–18 
In addition, recent studies on terminal agitation and 
death rattle have demonstrated the feasibility of RCTs in 
patients during the last days of life, if appropriate strate-
gies are implemented.22 77 82 Strategies include, but are 
not limited to, the use of advance or proxy consent, stan-
dardisation of care programmes, the application of short 
observation periods and the use of clinically implemented 
outcomes.22 75 82 While an RCT is the gold standard for 
demonstrating the efficacy of medication, continuous 
recording of routinely collected data would also enable 
researchers to conduct non- randomised comparative 
studies among treatment modalities. Below are unan-
swered questions and potential strategies to promote 
future research in terminal breathlessness (table 1).
what is the definition of terminal breathlessness?
Although widely referred to in clinical guidelines and 
systematic reviews, terminal breathlessness has not been 
formally defined.23 24 29 We herein propose a tentative 
definition of terminal breathlessness, that is, ‘breathless-
ness in patients with estimated life expectancy of weeks 
to days’. However, this may require further refinement by 
international experts.
how should we measure symptom intensity and patient 
discomfort related to terminal breathlessness?
From a pragmatic viewpoint, patient- reported outcomes 
(eg, breathlessness numerical rating scale (NRS), visual 
analogue scale, modified Borg scale) should be obtained 
as much as possible. If patient- reported assessment is 
not available as death approaches, then caregiver proxy 
rating (eg, NRS, IPOS, STAS) might be a reasonable alter-
native. In addition to caregivers’ proxy assessment, vali-
dated objective measurements by clinicians (eg, RDOS or 
Discomfort Scale for Dementia of the Alzheimer’s Type 
in pain and other discomfort assessment) could be used, 
although the correlation between patients’ subjective 
assessment of breathlessness and physiological findings 
is not established.83 A gold standard of breathlessness 
assessment in non- communicative patients should be 
urgently established.
are opioids and other treatment modalities effective and safe 
for terminal breathlessness?
Only a few prior studies explored the effects of morphine, 
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Table 1 Research questions regarding terminal breathlessness and future directions
Major research questions Strategies (examples)
1. What is the definition of terminal 
breathlessness?
 ► Conduct a Delphi study or organise taskforce discussions to achieve consensus on 
the definition of terminal breathlessness by international experts.
2. How should we measure symptom 
intensity and patient discomfort related 
to terminal breathlessness?
 ► Use patient- reported outcomes (eg, breathlessness NRS, VAS, modified Borg 
scale) as much as possible.
 ► Examine if the existing proxy rating scales (eg, NRS, IPOS, STAS, RDOS) are 
sufficient for cognitively impaired patients with terminal breathlessness; if not, seek 
a consensus on more valid and reliable proxy rating.
3. Are opioids and other treatment 
modalities effective and safe for 
terminal breathlessness?
 ► Conduct RCTs to examine the efficacy and safety of morphine and other opioids 
in the form of continuous infusion, parenteral benzodiazepines and corticosteroids 
(eg, parenteral morphine vs placebo; oxycodone vs placebo; hydromorphone vs 
placebo; corticosteroids vs placebo; or the comparison among these medications).
4. How should parenteral opioids 
be titrated, and does an upper 
limit of opioids exist for terminal 
breathlessness?
 ► Conduct RCTs comparing rapid versus slow titration, as well as morphine 
increment versus morphine plus midazolam for breathlessness refractory to low- 
dose morphine.
 ► Conduct a dose- finding study to clarify the effective and maximal dose of opioids.
5. Which patients benefit the most from 
treatment for terminal breathlessness?
 ► Conduct a large prospective cohort study to identify factors contributing to the 
response to or adverse events of opioids and other treatment modalities.
6. What non- pharmacological 
management is most effective for 
terminal breathlessness?
 ► Conduct RCTs to explore the efficacy and adverse events of oxygen therapy for 
terminal breathlessness in patients with cancer with or without hypoxaemia.
 ► Identify effective and feasible non- pharmacological modalities for terminal 
breathlessness other than fan therapy, and use non- pharmacological management 
as part of a multifaceted approach to patients with terminal breathlessness.
7. How should we define terminal 
breathlessness treatment goals 
and manage it if such goals are not 
achieved?
 ► Explore if personalised breathlessness goals that balance both breathlessness 
relief and maintenance of consciousness can be developed.
8. Are there promising novel treatment 
modalities for terminal breathlessness?
 ► Explore the benefit of novel medications (eg, sedatives).
 ► Collaborate with basic scientists to obtain more insights into the pathophysiology 
and modulators of the perception of terminal breathlessness, predictors of the 
treatment response and biologically targeted treatment.
9. How should family distress related to 
terminal breathlessness be managed?
 ► Conduct qualitative studies to identify in- depth experiences of families caring for 
patients with terminal breathlessness.
 ► Develop comprehensive interventions (eg, education, support) for family caregivers 
caring for patients with terminal breathlessness.
IPOS, Integrated Palliative care Outcome Scale;NRS, numerical rating scale; RCT, randomised controlled trial; RDOS, Respiratory Distress 
Observation Scale; STAS, Support Team Assessment Schedule; VAS, visual analogue scale.
breathlessness. Future high- quality RCTs should urgently 
examine the efficacy and safety of widely used modalities 
(eg, morphine and other opioids, benzodiazepines, and 
corticosteroids), as well as their psychoactive effects in the 
setting of declining consciousness in imminently dying 
patients with cancer with breathlessness.
how should opioids be titrated, and does an upper limit of 
opioids exist for terminal breathlessness?
Although the efficacy of opioids for cancer breathless-
ness has been demonstrated, how best to start and titrate 
them for terminal breathlessness remains unclear. Unlike 
chronic breathlessness where a majority of patients 
achieve breathlessness relief with low- dose sustained- 
release morphine orally (eg, 10–30 mg/day on a weekly 
titration),84 terminal breathlessness often requires the 
rapid titration of opioids.36 A systematic review of dose 
titration of opioids for cancer pain also revealed only 
limited evidence, and indicated that parenteral titra-
tion is more effective if it is important to achieve rapid 
symptom control (within hours).85
This lack of evidence results in a wide variability in 
the practice of treating patients with terminal breath-
lessness among palliative care specialists.32 37 A number 
of important clinical questions have yet to be answered. 
How should opioids be titrated orally or parenterally? 
How much should opioids be given as a rescue dose, and 
how frequently? What is the upper limit of opioids for 
terminal breathlessness? What pharmacological treat-
ment should be offered when further opioid titration is 
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events? All of these should be empirically confirmed by 
future studies such as prospective dose- finding studies 
and RCTs.
which patients benefit the most from treatment for terminal 
breathlessness?
Preliminary evidence indicated that approximately 
40%–90% of patients with terminal breathlessness 
achieved symptom relief 24 hours following the admin-
istration of parenteral opioids and/or midazolam.38 The 
rest of them continued to suffer breathlessness, had a 
decline in consciousness, or died. The predictors of the 
response to opioids remain largely unknown. A large 
prospective cohort study will be warranted to identify 
factors contributing to the response or adverse events of 
opioids and other treatment modalities.
what non-pharmacological management is most effective for 
terminal breathlessness?
Fan therapy is an easy, evidence- based non- 
pharmacological management for breathlessness in dying 
patients with cancer.64 As death approaches, however, 
holding a fan may become more burdensome. Supple-
mental oxygen might be a good alternative in gently stim-
ulating V3 areas, even if no hypoxia is noted; however, 
there is a dearth of literature to support/refute the use 
of supplemental oxygen in this setting. Moreover, clinical 
trials are warranted to explore the efficacy and adverse 
events of oxygen therapy for terminal breathlessness 
in patients with cancer irrespective of the presence of 
hypoxaemia. Effective and feasible non- pharmacological 
modalities for terminal breathlessness other than fan and 
oxygen therapy should also be identified, and used as 
part of a multifaceted approach to patients with terminal 
breathlessness.
how should we define terminal breathlessness treatment 
goals and manage it if such goals are not achieved?
Most patients wish to have symptom relief and remain 
mentally aware at the end of life.86 However, imminently 
dying patients tend to show a decline in consciousness 
associated with organ dysfunction as part of the natural 
dying process, irrespective of the use of opioids and/
or sedatives.6 8 32 In addition, terminal breathlessness 
may become refractory to standard symptom manage-
ment, and sometimes require palliative sedation. Thus, 
the management of terminal breathlessness needs to 
take into account a delicate balance of trade- off between 
breathlessness relief and maintenance of consciousness.32 
Best balance of the trade- off highly depends on patients’ 
goals and preferences. For example, imminently dying 
patients waiting for family members who live far away to 
arrive may want to minimise the use of medications with 
sedative effects, whereas those who prioritise physical 
comfort may ask clinicians to maximise the use of medica-
tions for symptom control even if there is a risk of losing 
consciousness.
To provide goal- concordant care, individuals’ goals 
and needs for further treatment should be clarified by 
patients themselves or their loved ones if their conscious-
ness level has declined. How to measure personalised 
symptom goals needs to be established.87
are there promising novel treatment modalities for terminal 
breathlessness?
Very few medications other than opioids and midazolam 
have been demonstrated to be effective for patients with 
terminal breathlessness. The net benefit of breathless-
ness treatment might be limited with the optimisation 
of existing modalities alone. To achieve more efficient 
breathlessness relief, novel modalities should be explored.
Basic science has begun to explore factors contrib-
uting to the response to opioids. For example, a recent 
exploratory study in palliative care patients on opioids 
identified a biologically plausible single nucleotide poly-
morphism that was associated with breathlessness inten-
sity.88 However, it remains unclear if interventions with 
efficacy in patients with a life expectancy of months can 
be applied with similar efficacy in patients with terminal 
breathlessness in whom pharmacokinetics of medications 
and goals of care may differ. Future development of basic 
science and translational research are warranted to obtain 
more insights into pathophysiology and modulators of 
perception of terminal breathlessness, predictors of treat-
ment response and biologically targeted treatment.
how should family distress related to terminal breathlessness 
be managed?
A bereaved family survey indicated that families feel less 
necessity of improvement if the clinicians had ensured 
their loved one’s comfort and coached the family on how 
to care for the patient.89 Qualitative studies can identify 
in- depth experiences of families caring for patients with 
terminal breathlessness. Comprehensive interventions 
(eg, education, support) for family caregivers of patients 
with terminal breathlessness might enhance families’ self- 
efficacy, relieve their distress and help patients and fami-
lies spend the last days of life as they desire.
ConClusIon
In conclusion, there is little evidence to support the 
concept, assessment and management of terminal 
breathlessness in patients with cancer. Future research is 
urgently needed to define, measure and manage terminal 
breathlessness, which would allow patients to express their 
hopes regarding care and engage in decision- making 
at the end of life; families to provide informal support; 
clinicians to closely monitor and provide necessary treat-
ment; researchers to develop appropriate treatment strat-
egies; and health services to implement care pathways to 
achieve patient goals effectively.
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